

Index

a

- activity-based probe (ABP)
 - vs. affinity-based probes (AfBPs) 53–60
- bioorthogonal ligation chemistry 57
 - CuAAC 58–59
 - Diels–Alder reaction 59–60
 - SPAAC 59
 - Staudinger ligation 58
- warheads (reactive groups)
 - electrophilic warheads 55
 - linkers 56–57
 - photocrosslinking warheads 55–56
 - reporter tags 56
- activity-based protein profiling (ABPP) 51, 65
 - case study
 - ABPP for enzyme identification 65–68
 - FAAH inhibitor 68–70
 - PAL 74–80
 - qABP 80–82
 - sulforaphane, target profiling 71–73
 - USP inhibitors, profiling 73–74
- acute myeloid leukaemia (AML) 117, 120–121
- acyloxymethyl ketone (AOMK) 55, 81, 82
- affinity-based chemoproteomics, target identification
 - mode of action 43–44
 - phenotypic mechanism of action elucidation 29–30
 - quantitative high-resolution mass spectrometry 30–33
 - target validation 43–44
- affinity-based probes (AfBP) 53–60
- affinity-based protein profiling (AfBPP) 53
 - affinity probe, design of 34–36
 - affinity purification 32, 43, 45, 61
 - nonselective kinase-binding 32
 - alkyne/strained alkene 58
 - amidated lipids 68
 - amino-sepharose beads 109
 - ampicillin 59
 - anandamide (AEA) 68
 - androgen receptor (AR) 213, 328
 - andrographolide 59
 - antigen-presenting cells (APCs) 80
 - Archaea species 66, 68
 - Archazolid A 283, 291
 - aryl azides 55
 - aspirin 59
 - ATP-binding scaffold 220
 - automatic gain control (AGC) 112
 - AUX/IAA protein-derived degron-tags 222
 - auxin-inducible degradation (AID) system 222, 223
 - auxotrophy 63
 - azide-TAMRA-biotin (AzTB) 60, 71
 - AzRTB 57

b

- base editing 254
- Bayes affinity fingerprints 294
- Bayesian multi-class models 293, 294

- BCL6 215, 216
 - BCR-ABL inhibition 220
 - bead washing conditions 103
 - benzophenones 40, 55
 - binding constant 105, 113
 - BioGRID 335
 - bioinformatics
 - biological pathways 339
 - image-based data 348–357
 - MoA 323–324
 - process of pathway analysis 341
 - transcriptomics data and databases
 - Connectivity Map (CMap) 327–331
 - Library of Integrated Network-based Cellular Signatures (LINCS) 331–339
 - transcription process 326–327
 - biological pathways 135, 168, 258, 259, 308, 326, 337, 339, 341, 342, 346, 357
 - bioluminescence resonance energy transfer (BRET) 102
 - biomarkers
 - correlation of 214–219
 - direct target engagement 212–213
 - drug response 214
 - indirect target engagement 213–214
 - pathway 213–214
 - types of 211
 - bioorthogonal amide coupling 39
 - bioorthogonal ligation chemistry 57
 - CuAAC 58–59
 - Diels–Alder reaction 59–60
 - SPAAC 59
 - Staudinger ligation 58
 - bioorthogonal reactions 57, 58
 - Bradford assay 107, 110
 - BRD9 inhibitors 12–14, 228, 229
 - bromodomains (BRD) 9, 12, 221, 226, 228, 229
 - “bump-and-hole” approach 219–222, 224
- C**
- Cabozantinib 117, 120–121
 - cap analysis of gene expression (CAGE) technique 241
 - Cas9 cleavage activity 246
 - catalytic-dead Cas9 (dCas9) 250, 253
 - CATDS scoring scheme 100
 - cathepsin S 80–82, 149
 - cDNA 227, 228, 331
 - celestrol 328
 - cell-based thermal shift assay (CETSA) 44, 131–150
 - cell biology methods, target validation
 - biomarkers 211–219
 - cellular response
 - bump-and-hole approach 219–222
 - chemogenomic approach 222–226
 - resistance conferring mutations 226–229
 - cell cycle pathway 339, 340
 - Cell Image Library 349
 - cell morphology enrichment analysis 356
 - cell painting assay 193, 195, 349, 351, 354
 - cell-penetrating peptides (CPPs) 252
 - CellProfiler 193, 298, 349, 350, 354, 355
 - cell/tissue lysate 33, 63, 101, 107, 115–116
 - cellular response
 - bump-and-hole approach 219–222
 - chemogenomic approach 222–226
 - resistance conferring mutations 226–229
 - cellular thermal shift assay (CETSA) 44, 131–150
 - central nervous system (CNS) 165, 298, 328
 - cereblon (CRBN) 223
 - ChemBank 279
 - ChEMBLSpace 302
 - chemical labelling quantification 30–32, 61–63
 - chemically advanced template search (CATS) 285
 - chemical probes 2–14, 16–19, 29, 51, 74, 78, 98, 100–104, 109, 118, 119, 123, 124, 131, 197, 288

- Chemical Similarity Network Analysis
 - Pulldown (CSNAP) 288
- chemical strategies, new drug targets
 - biological target panels and profiling 8–10
 - chemical probes, development
 - from BIX01294 to EPZ035544 10–12
 - BRD9 inhibitors 12–14
 - chemogenomic libraries 5–6
 - compound based target evaluation 14–15
 - inactive control 6–8
 - patient-derived cell assays 16
 - target evaluation approach 16–17
- chemogenomic approach 3, 222–226, 331
- chemogenomic compound 5–10, 19
- chemogenomic libraries 3, 5–6, 29
- chemogenomics 3, 4, 294
- chemoproteomic-guided medicinal chemistry
 - drug discovery 121–122
 - lead discovery 122
 - lead optimization 122
- chemoproteomics 25–45, 100–105, 116, 121–125, 211
- chromophore assisted light inactivation (CALI) 190
- chronic myeloid leukaemia (CML) 98, 120, 260, 339
- click reaction 58, 70
- clustered regularly interspaced short palindromic repeats (CRISPR) reagents 26, 182, 211, 234, 237–238, 241
- coactivator associated arginine methyltransferase 1 (CARM1) gene 225
- coherent anti-stokes Raman Scattering microscopy (CARS) 190
- colorimetric protein quantification assays 107
- compound based target evaluation 14–19
- compound selectivity 98, 100, 117
- Connectivity Map (CMap) 198
- MoA deconvolution
 - compound's gene expression 328–330
 - gene expression profiles 330–331
- context likelihood of relatedness (CLR) algorithm 356
- convolutional neural networks (CNNs) methods 193, 296
- copper(I)-catalysed alkyne-azide cycloaddition (CuAAC) 58–59
- copy number variations (CNVs) 158, 240
- coronary artery disease (CAD) 172
- correlation, biomarkers 214–219
- corticosteroids 198
- CRISPR/Cas technology 184, 221, 234, 237, 238, 250, 259, 263
 - anticipated knockout / knock in 252
 - base editing 254
 - biological and genomic aspects 239–242
 - CRISPRa 253
 - CRISPRi 253
 - delivery vehicle and cargo 249, 251
 - general principle and considerations 256–258
 - gRNA design
 - predictive tools 247–248
 - spacer sequences 245–246
 - target locations identification 242–245
 - immunology studies 260–262
 - mechanistic aspects 237
 - methodology 238–239
 - in prokaryotes 237
 - target discovery 255–257
 - target validation 254–255
- CRISPRi 253
 - applications 241
- CRISPR RNA transcripts (crRNAs) 237
- cross-pharmacology index (XPI) 287
- CSNAP3D 289
- cutting frequency determination (CFD) score 248
- cyclooctyne 59
- cysteine cathepsins 58, 80–82
- cystic fibrosis (CF) 80, 171

- cystic fibrosis transmembrane
conductance regulator (CFTR)
gene 171
cytochrome P450 enzymes 59
Cytoscape 302
- d**
- data dependent acquisition (DDA) 112
deep learning techniques 296, 336
deep neural networks (DNN) 292
degradation 213, 215, 216, 222–226
degradation tag (dTAG) 222, 224
dendritic cells (DCs) 80, 115, 261
deubiquitinating enzymes (DUBs) 56,
73
deubiquitination 73
diacylglycerol lipase (DAGL) inhibitor
59
diazirines 40, 54, 55
diazobenzenes 57
Diels–Alder reaction 59–60
differential scanning fluorimetry (DSF)
44
dihydrofolate reductase (DHFR) 142
direct target engagement biomarkers
212–215
disulfides 57
double strand break (DSB) 235, 238,
247, 252
downstream effector 141
drugCIPHER 304
drug discovery 153
process 179, 180, 324
projects 214, 219
druggable kinome 117
drug-induced liver injury 180
drug-network (DN) 346–347
drug pathway enrichment analysis 302
drug profile matching approach (DPM)
302
drug response biomarker 214
- e**
- electrophilic warheads 55
E3 ligase 223, 224
embryonic stem cells (ESCs) 240
enzymatically cleavable linkers 57
enzyme mismatch cleavage (EMC)
assays 252
epidermal growth factor receptor
(EGFR) 117, 156, 348
epoxide warheads 64
estrogen receptor α (ER α) 292
European Society for Medical Oncology
Magnitude of Clinical Benefit
Scale (ESMO-MCBS) 181
extended-connectivity fingerprints
(ECFP) 284
- f**
- false discovery rate (FDR) 112
FANTOM database 241
fatty acid amide hydrolase (FAAH)
inhibitor 68–70
F-box protein 222, 223
feature pairs (FPD) 286
ferrochelatase (FECH) 113, 147
FKBP12 224–226
flaviviruses 259
fluorescence-quenched activity-based
probes (qABPs) 65
fluorescence recovery after
photobleaching (FRAP) 190
fluorescence ubiquitination cell cycle
indicator (FUCCI) 190
fluorogenic BODIPY-tetrazine 59
fluorophores 57, 131
fluorophosphonate-biotin (FP-biotin)
55
fluorophosphonate (FP) probes 64, 70
fluorophosphonate warhead 66
focal adhesion kinase (FAK)
198
focal cortical dysplasias 162
focused or iterative library screening
144
forward chemical genetics 325
fragment-based lead generation (FBLG)
144
fragment library screening 144–145
frequent hitter filters 38
FTO gene 160
functional genomics 170, 173,
193–195

functional validation 164–170, 221
Funrich package 356–357

g

G9a/GLP inhibitors 10–12
gain-of-function mutations 170
gastro-intestinal stromal tumors (GIST) 120
gedunin 199, 328
GeneCards 165
gene knockdowns (KD) 226, 334, 339
GeneMatcher 165
gene set enrichment analysis (GSEA) 337
genetic manipulation technology
 CRISPR/Cas technology 237
 RNAi 234–237
 TALENs 234–236
 ZFNs 235
genetic redundancy 240
gene transcription-based profiling 198
genome-wide association studies
 (GWAS) 154, 158–161, 163, 168, 172
Genomics of Drug Sensitivity in Cancer (GDSC) 348
Gibbs free energy 103, 104
Gini coefficient 100
glioblastoma (GBM) 123, 201
glucosinolate metabolism 71
goitrin 291
G-protein-coupled-estrogen receptor (GPER) 347
G-protein coupled receptors (GPCR) 3, 38, 135, 213, 288, 347
graveolinine 291
group factor analysis (GFA) method 347

h

Haloferax volcanii 66, 68
HapMap project 158
high-content co-culture assays 192
high content imaging 190–193, 195, 203
high-content screening (HCS) 183, 191, 294, 298

higher energy collision-induced dissociation (HCD) 112
high-throughput dynamic light scattering 132
high-throughput screening (HTS) 27, 74, 121, 140, 142, 324
high-throughput screening fingerprints (HTS-FP) 297, 298
histone deacetylase (HDAC) inhibitor 148
histone-3 lysine-9 di-methylation (H3K9me2) 10
human bone osteosarcoma epithelial cells 349
human cell based model systems
 CRISPR genome editing 184
 high content imaging 190–191
 in vivo imaging 188–190
 iPSC 185
 multiparametric high content imaging
 cell painting 193–195
 cell phenotypes 191
 chemical design and target selectivity 195–196
 phenotypic fingerprint 191
 phenotypic heterogeneity 193
 quantitative pathway profiling
 dose-response and time-series 199–202
 gene transcription level 198–199
 3D cell and organoid models 185–186
human foetal haemoglobin 12
Human Protein Reference Database (HPRD) 335

i

Imatinib (Gleevec) 97, 220, 341
immunohistochemistry (IHC) 201
inactive control compound 3, 6, 17
in-cell light-activated affinity-based chemoproteomics
 experimental workflow 40–43
 limitations 43
 reactive photo-affinity probe (PAL probe) 40

- indirect target engagement biomarkers 213–214
 - induced pluripotent stem cells (iPSC) 29, 168, 180, 184–185, 234, 291
 - inflammatory bowel disease (IBD) 18–19
 - Ingenuity® Pathway Analysis (IPA) 73
 - inhibitor polypharmacology
 - cabozantinib repositioning 120–121
 - drug repositioning 120
 - in-lysate affinity-based chemical proteomics
 - affinity probe, design of 34–36
 - general experimental pull-down workflow 36–38
 - limitations 38–39
 - 'in lysate' affinity-based chemoproteomics 28
 - insertion/deletion (indel) mutations 239
 - in-silico target identification
 - fragment-based approaches 290–292
 - molecular descriptors 297–299
 - protein-protein and ligand-target networks 302–304
 - publically available tools 280, 282
 - QSAR models 292–297
 - structure-based screening methods 299–302
 - target inference
 - 3D similarity methods 289
 - 2D similarity methods 283
 - in situ* affinity-based chemoproteomics 28, 39
 - International Mouse Phenotyping Consortium 166
 - intracellular affinity 103
 - inverse electron-demand Diels–Alder (IEDDA) 59
 - inverse Rapid Index-based Screening Engine (iRAISE) 299
 - isobaric labelling 62
 - isobaric tags for relative and absolute quantitation (iTRAQ) 32
 - isomacrolin 291
 - isothermal calorimetry (ITC) 44
 - isothermal dose response fingerprints (ITDRFs) 133
 - isotope-coded affinity tag (ICAT) labelling 61
 - isotopic tagging reagents 32
- k**
- Kelch-like ECH-associated protein 1 (KEAP1) 73
 - Ki-67 labelling 201
 - kinase inhibitor, chemical proteomics
 - binding affinity, determination 104–105
 - binding assay, design 103–104
 - chemoproteomic profiling
 - comparison 102–103
 - kinobeads technology 100–102
 - polypharmacology, of small molecule kinase inhibitors
 - kinase inhibitor binding 98
 - protein kinases and their inhibitors 97–98
 - selectivity metrics 98–100
 - KiNativ technology 102
 - Kinobeads 9, 103–105, 123–125
 - assay 105
 - competition assay 110, 111
 - ϵ -version of 110
 - γ -version of 110
 - protocol
 - affinity matrices 107–110
 - cell/tissue lysate 107
 - data analysis 112–113
 - kinobeads competition assay 110–111
 - mass spectrometry 111–112
 - pull-down assay 105
 - target space deconvolution
 - CHEK1 inhibitors 117–119
 - irreversible inhibitors 119
 - mode of action, analysis 116–117
 - target space expansion
 - affinity probes 113–115
 - cell or tissue lysate 115–116

technology 100–102
 workflow 101
k-nearest neighbour (kNN) statistics
 286, 296
 Kyoto Encyclopaedia of Genes and
 Genomes (KEGG) 165–166,
 339, 342, 345, 346

I

label-free imaging techniques 190
 label-free method 45, 131–133, 139,
 147, 149, 150
 label-free quantification (LFQ) 61, 62,
 107, 112, 113, 149
 label-free screening 143
 label-free techniques 131
 CETSA 132
 classics 136–138
 HT 138–140
 MS 140–142
 nucleotide metabolism 132
 protein detection 134
 protein band 133
 target discovery
 active hit molecules, generation
 142–143
 target classes 143–144
 tool generation 143
 least absolute shrinkage and selection
 operator (LASSO) 356
 leave-one-out cross validation
 (LOOCV) 335, 356
 Library of Integrated Network-Based
 Cellular Signatures (LINCS)
 L1000 data in MoA understanding
 bioactive compounds 337–338
 gene expression profiles 334
 predict activatory and inhibitory
 targets 338–339
 LINCS L1000 data exploration
 332–333
 ligand–protein interactions 103, 289
 ligand-target networks 302–304
 linkage disequilibrium (LD) 159
 lipid membrane shields 135
 lipid metabolism pathways 70
 5-lipoxygenase (5-LO) 291

lncRNA Xist splicing 241
 loss of function (LOF) 148, 155, 156,
 220, 242, 245, 253, 255
 low-density lipoprotein (LDL) receptors
 155
 lysine acetylation (Kac) 12

m

machine learning algorithms 292
 macromolecular data service (MMDS)
 299
 marinopyrrole A 286
 mass differential tags for relative and
 absolute quantitation (mTRAQ)
 32
 mass spectrometry (MS) 30–33, 51,
 56, 57, 61, 62, 101, 111–112, 198,
 199
 Mathew's correlation coefficient (MCC)
 356
 MaxQuant 33, 107, 112
 mechanism-of-action (MOA) 26, 182
 CMap
 compound's gene expression
 328–330
 gene expression profiles 330
 deconvolution 328–331
 elucidation 27, 44, 354–357
 image-based data
 cellular morphology 350–353
 chemical/genetic perturbations
 354–357
 cluster compounds 350–353
 drug repositioning and biological
 activity prediction 353–354
 L1000 data in
 bioactive compounds 337–338
 gene expression profiles 334
 predict activatory and inhibitory
 targets 338–339
 vs. mode of action 323–324
 pathways analysis
 drug-network 346–347
 PROGENy 347–348
in silico target predictions 345
 target prediction 325–326
 metabolic labelling 32, 61, 63

- metalloproteases 56
 - microfluidic assay formats 189
 - microfluidic device 191, 201
 - microtiter plate-based HT format 140
 - migration inhibitory factor (MIF) 73
 - mismatch detection assay (MDA) 252
 - mode of action (MoA) 43–44, 59, 68, 71, 73, 98, 116–119, 123, 124, 141, 323–324
 - Mode of Action by NeTwoRk Analysis (MANTRA) 346, 347
 - Molecular Libraries Program (MLP) 288
 - monoglyceride lipase (MGLL) 199
 - Morphobase 350, 353
 - mTOR pathway 162, 170
 - multi-targeted drug combination therapy 182
 - MYC target genes 223
- n**
- Naïve Bayesian classification 293, 294
 - NanoBRET assay 102
 - nanoclews 252
 - National Cancer Institute (NCI) 345
 - negative control compounds 218, 219
 - next generation sequencing (NGS) 163, 180, 183–184, 241
 - NHS-activated sepharose beads 107, 109
 - NHS-Sepharose beads 109
 - N*-hydroxysuccinimide (NHS) 32, 37, 107, 110
 - nitrophenol ethyl phosphonate probe (NP) 66
 - N*-myristoyl transferase (NMT) inhibitors 57
 - nonsense-mediated decay (NMD) pathway 242
 - non-viral vector delivery 251
 - normalized collision energy (NCE) 112
 - nucleotide metabolism 132
- o**
- oesophageal adenocarcinoma (OAC) 184, 185
 - omipalisib 107, 110, 115
 - o*-nitrobenzenesulfonyl (*o*NBS) 109
 - Online Mendelian Inheritance in Man (OMIM) 154, 160
 - Open PHACTS Discovery Platform 279
 - organoid models 182, 184–186
 - organ-on-a-chip devices 183, 186–188
 - orlistat 59
 - orthogonal pharmacology 140
- p**
- para*-nitrophenol octanoate ester 68
 - partial least squares (PLS) 292, 294
 - passenger mutations 181
 - pathway biomarkers 213–215
 - Pathway RespOnsive GENes (PROGENy) 347, 348
 - patient-derived cell assays 16, 184, 201
 - Pegvaliase 161
 - peptide and protein identification 112
 - Pharmacophore ActivityProfiler 290
 - pharmacophore fragments (PHRAG) 286, 287
 - pharmacophore models 290, 306
 - phenotypic clusters 195, 196
 - phenotypic hit deconvolution 145–147
 - phenotypic mechanism of action elucidation 29–30
 - phenotypic screening (PS) 25, 51, 124, 142, 196–197, 277–279, 291, 293, 325
 - phenylalanine hydroxylase (PAH) 148, 149, 161
 - phenylketonuria (PKU) 148, 161, 170
 - Philadelphia (Ph) gene 339
 - photoaffinity labelling (PAL) 40, 42, 43, 74–80
 - photocrosslinking warheads 55, 56
 - photo-reactive affinity ligation (PAL) 39
 - photo-reactive affinity probe 39, 40
 - photosensitive cleavable linkers 57
 - pinosylvin 347
 - piperazine phenothiazine antipsychotics (PhPAPs) 328
 - Plasmodium falciparum*, 116

- Polypharmacology Browser version2 (PPB2) 293, 294
- post-translational modifications (PTMs) 51, 66, 102, 115, 200
- precision medicine 120, 123, 170–172
- prediction of activity spectra for substances (PASS) 292
- pregnane-X receptor (PXR) 295
- pre-incubation, of lysate 111
- premature termination codons (PTCs) 239, 242, 244
- principal component analysis (PCA) 353
- principle components (PC) scores 353
- ProbeMiner 10
- proprotein convertase subtilisin/kexin type 9 (PCSK9) antibodies 155, 156
- prostaglandin reductase 2 (PTGR2) 78, 79
- proteasome inhibitor 59, 346, 347
- protein-dependent correction factor 113
- protein detection 27, 30–33, 134, 136, 140
- protein-lipid interactions 56
- protein lysine methyltransferases (PKMTs) 10
- protein–protein interaction (PPI) 51, 78, 97, 143, 190, 226, 304, 334
- proteolysis targeting chimeras (PROTACs) 213, 223, 226
- proteome-wide myristoylation 57
- proteomics in forward chemical genetics (PDD) 26, 29–30, 45
- protospacer adjacent motif (PAM) 238, 242, 246–248, 254, 262
- q**
- quantitative chemical proteomic methodology 74
- quantitative high-resolution mass spectrometry 27, 30–33
- quantitative proteomic approach 40, 62
- quantitative proteomics, by mass spectrometry 61
- chemical labelling quantification 61–63
- LFQ 61
- metabolic labelling quantification 63
- quantitative structure-activity relationship (QSAR) 280, 283, 287, 292–297
- quenched fluorescent activity-based probe (qABP) 65, 80–82
- r**
- random forest (RF) 292, 334
- Rapid Overlay of Chemical Structures (ROCS) 289, 290
- reactive oxygen species (ROS) 190
- Reactome 342
- receiver operating characteristic curve (ROC-AUC) 296
- reporter tags 43, 53, 56, 57, 60, 66, 71
- resistance conferring mutations 226–229, 254
- reversed chemical genetics (TDD) 26, 30, 324
- reverse phase protein array (RPPA) 200, 201
- reverse translation 181
- data integration 172–173
- drug discovery 154–156
- drug targets
- data analysis 163–164
- GWASs 159
- rare disease genetics 160–161
- somatic mutations 162
- functional validation
- druggable target 170
- model system 168–169
- publicly available data 165–166
- putative mutations 165
- systems biology 166–168
- precision medicine 171–172
- rhodamine-azide (Rho-N₃) 66
- rhodamine-biotin-azide (Rh-Biot-N₃) 66
- RNA interference (RNAi) 44, 211, 220, 226, 229, 234

S

Sanger sequencing 252
second harmonic generation (SHG) 190
selectivity metrics 98–100
self-organising maps (SOM) 285, 286, 291
Shannon entropy descriptors (SHED) 286, 287
short hairpin ribonucleic acids (shRNAs) 26, 79, 199, 235, 255, 331, 334
short interfering RNA (siRNA) 146, 147, 170, 234
siamese neural network method 336
sickle cell anaemia 10, 12
signal transducer and activator of transcription (STAT) 73
similarity ensemble approach (SEA) 284, 285, 298
single-cell barcode chip (SCBC) 201
single-cell immunofluorescent-based format 140
single gRNA (sgRNA) 238, 242, 255, 260, 261
single nucleotide polymorphisms (SNPs) 158–160, 241, 244, 248, 252
Skp, Cullin, F-box (SCF) 222
smallest active subgraphs (SAS) 287
SMILES 296, 297
sodium dependent serotonin transporter (SERT) 288
sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) 38, 56, 110
somatic mutations 162, 181
spacer sequences
 off-target activity 247
 on-target activity 246
SPiDER-method 286, 291
stable isotope labelling 32, 61, 63
stable-isotope labelling by amino acids in cell culture (SILAC) 32, 37, 63, 70, 73, 76
StarGazer 132
Staudinger ligation 58
stem-cell-derived cardiomyocytes 180

strain promoted alkyne-azide cycloaddition (SPAAC) 59
Structural Genomics Consortium 2, 197
structure activity relationship (SAR) 34, 76, 114, 144, 195, 196, 277, 337
structure-based design (SBDD) 12, 13, 121, 299
substrate protein phosphorylation 99
SunTag-binding domain 253, 260
supernatant 109–111, 133
support vector machines (SVM) 292, 296, 298, 306
surface plasmon resonance (SPR) 44, 132, 147
surveyor assay 252

t

tandem mass tags (TMT) 32, 33, 61, 63, 107
Tanimoto distance metric 196
TarFisDock-webserver 302
target discovery, CRISPR/Cas technology 255–256
target engagement (TE) 44, 74, 119, 131, 195, 212–213, 219, 236, 254
Target Inference Generator (TIGER) approach 285
target prediction 285, 288, 293, 296, 297, 307, 323–326, 330–331, 345–336, 350–353
T7 endonuclease 1 (T7E1) 252
thermal proteome profiling (TPP) 28, 136–138
thermal shift assay (TSA) 10, 44, 131, 135
thermoFluor technique 132
3D cell culture 185, 186
(3D) *ex-vivo* tissue 182
3D spheroid assays 187
tissue lysates 33, 63, 101, 107, 115
TNF-related apoptosis-inducing ligand (TRAIL) 279
tobacco etch virus (TEV) 57
topoisomerase 2 alpha (TOP2A) 327

- Tracking of Indels by Decomposition
(TIDE) assay 252
- trans-activating crRNA (tracrRNA)
238
- transcription activator-like effector
nucleases (TALENs) 234–237,
253, 254
- transcriptional amplifier 223
- transcription factor IIIA (TFIIIA) 235
- transcription start sites (TSS)
annotations 241
- transport inhibitor response 1 (TIR1)
222
- trifluoromethyl phenyl diazirine 40
- u**
- ubiquitination 73, 190
- ubiquitin specific protease (USP) 73,
74
- upstream open reading frame (uORF)
245
- v**
- van Buchem syndrome 162
- vinyl ketone 64
- vitamin D receptors (VDR) 14
- von Hippel–Lindau tumor suppressor
(VHL) 223, 226
- w**
- warheads (reactive groups)
electrophilic warheads 55
linkers 56–57
photo crosslinking warheads 55–56
reporter tags 56
- whole genome sequence (WGS) 19,
155, 163, 181, 183, 229
- WikiPathways 342
- x**
- xenobiotic drug-metabolizing enzymes
70
- X-ray crystallography 12, 148, 299
- y**
- Yao’s minimalistic linkers 40
- z**
- zebrafish 59, 116, 168, 169, 236, 247,
285
- ZINC database 285, 336
- zinc-finger nuclease (ZFN) 234–237

